Clinical Trial Update: HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma [Phase 4]

View source ↗

Summary

Phase 4 trial update of HD IL-2 plus vemurafenib in patients with BRAF mutation-positive metastatic melanoma; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HD IL-2
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Clinigen, Inc. | Conditions: Metastatic Melanoma | Phase 4 | Status: TERMINATED